OnCo

Uveal melanoma: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Screening, prevention and diagnosis1
Advanced, first line2
Other settings1

Screening, prevention and diagnosis

SubgroupSettingApproachProducts and trialsEvidence
All comersSurveillanceRisk-adapted liver imaging (MRI/ultrasound) every 6-12 months for high-risk GEP class 2 / monosomy 3; no proven adjuvant therapy.40

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersMetastatic, HLA-A*02:01-positiveTebentafusp weekly (OS 21.7 vs 16.0 months vs investigator's choice); manage cytokine release and rash.81
All comersMetastatic, HLA-A*02:01-negative or liver-dominantPercutaneous hepatic perfusion with melphalan (FOCUS trial; approved 2023), radioembolisation, hepatic resection; ipilimumab-nivolumab (~15% response); clinical trials (darovasertib-crizotinib).89

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersPrimary tumourPlaque brachytherapy (I-125 or Ru-106) or proton beam radiotherapy for most; enucleation for large tumours; prognostic biopsy for GEP/chromosome 3.40

Regimens in the library

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.